Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Canadian-under $3.00 Stock-Picking Challenge -- Ignore unavailable to you. Want to Upgrade?

To: originunknown who wrote (4182)	10/14/2001 12:49:53 PM
From: Al Collard	Respond to of 11802

Hi OU, Your in with IMM-v @$.07 for 142,857 shares. Chart for Immune Network Research Limited: stockcharts.com[l,a]djcanimy[dc][pc20!b50!b100!b200!f][vc60][iUb14!Ll14!La12,26,9!Lh14,3!Lc20] The chart of IMM shows a picture of a troubled stock with no clear direction. The Slow Stoch's is suggesting the stock is overbought but the MACD has turned positive with the ADX showing no clear trend. All in all a pretty muddled picture. Obviously this stock needs a dose of good news. Good luck with this pick, Al

To: originunknown who wrote (4182)	10/16/2001 5:40:00 PM
From: Al Collard	Respond to of 11802

OU, news out on your pick IMM-v: Immune Network co-develops drugs with Nutraceutix Tue 16 Oct 2001 The Canadian Venture Exchange has accepted for filing documentation with regard to an agreement in principle dated Oct. 12, 2001, between the company and Nutraceutix, Inc. Under the agreement, the company and Nutraceutix have agreed in principle to co-develop novel formulations of existing gerontology drugs. Subject to a formal agreement, Nutraceutix will grant the company a license to employ Nutraceutix's proprietary controlled delivery technology in the development and manufacture of an anti-inflammatory and antimicrobial product containing dapsone (the product). Nutraceutix will develop modified release forms of the product for the company and will arrange to have the product manufactured that meets all applicable legal and regulatory requirements and standards applicable to the manufacturing and distribution of the product. The company will pay a non-refundable fee of $200,000 and $100,000 for scale up and a single clinical trial batch of the product, excluding raw materials. No securities of the company are issuable.